What is Supernus Pharmaceuticals's ONAPGO — total revenues?

Supernus Pharmaceuticals (SUPN) reported ONAPGO — total revenues of $8.38M in Q1 2026.

What does ONAPGO — total revenues mean?

This metric represents the total gross revenue generated by the specific product line or business segment during the reporting period. It serves as a primary indicator of the segment's market adoption, commercial success, and contribution to the company's overall top-line financial performance.

Supernus Pharmaceuticals (SUPN) ONAPGO — Total revenues

Screener

Other product segments

Qelbree

$77.84M+20.2%

GOCOVRI

$35.24M+14.8%

Royalty, licensing, and other revenues

$29.31M+274%

Collaboration revenue (ZURZUVAE)

$27.64M—

Trokendi XR

$9.48M-26.0%

APOKYN

$7.73M-48.4%

Oxtellar XR

$7.42M-27.2%

Other

$4.67M-45.6%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.72B+14.3%

Enterprise value$2.57B+13.6%

P/S3.5×-0.1×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 4:15 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001356576-26-000022

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Qelbree	$77,843	$64,745
GOCOVRI	35,240	30,689
Trokendi XR	9,479	12,801
ONAPGO	8,375	—
APOKYN	7,728	14,976
Oxtellar XR	7,422	10,198
Other(1)	4,666	8,579
Total net product sales	150,753	141,988

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's ONAPGO — total revenues?: Supernus Pharmaceuticals (SUPN) reported ONAPGO — total revenues of $8.38M in Q1 2026.
What does ONAPGO — total revenues mean?: This metric represents the total gross revenue generated by the specific product line or business segment during the reporting period. It serves as a primary indicator of the segment's market adoption, commercial success, and contribution to the company's overall top-line financial performance.